open access

Vol 81, No 2 (2010)
ARTICLES
Get Citation

Prostate specific antigen - PSA and histopathological findings of endometrium in women with fibrocystic breast disease

Stanisław Radowicki, Michał Kunicki
Ginekol Pol 2010;81(2).

open access

Vol 81, No 2 (2010)
ARTICLES

Abstract

Abstract Objective: The aim of the study was to evaluate the relationship between serum free and total PSA and histopathological findings in women with fibrocystic mastopathy. Material and methods: 176 women with fibrocystic breast disease, aged 18 to 45 years. - group I: comprised 114 patients with cysts <10mm in diameter - group II: comprised 62 women with cysts >10mm in diameter The control group consisted of 46 healthy women aged 18 - 45 years who had no breast pathology. Total PSA (PSA-T) and free PSA (PSA-Free) were measured by an ultra-sensitive fluoroimmunometric DELFIA assay (Prostatus PSA Free/Total Wallac, Turku, Finland). The detection limit for PSA was 0.01 ng/ml. Endometrial samples have been obtained with Pipelle probe between 22 and 24 days of the menstrual cycle. Results: In the control group secretory endometrium was more frequently detected than in the mastopathy group (chi2=11,15, p=0.01). Proliferatory (chi2=8.27, p=0.004) and presecretory endometrium (chi2=4.61, p=0.03) were more frequently detected in the mastopathy group than in controls. We did not find statistically significant relationship between the mean PSA concentrations between the groups in relation to histopathological findings. Conclusions: No relationships between free and total PSA measured in the follicular phase of the menstrual cycle and endometrial findings were detected in our study. Further research is required to evaluate the relationship between PSA and endometrial findings.

Abstract

Abstract Objective: The aim of the study was to evaluate the relationship between serum free and total PSA and histopathological findings in women with fibrocystic mastopathy. Material and methods: 176 women with fibrocystic breast disease, aged 18 to 45 years. - group I: comprised 114 patients with cysts <10mm in diameter - group II: comprised 62 women with cysts >10mm in diameter The control group consisted of 46 healthy women aged 18 - 45 years who had no breast pathology. Total PSA (PSA-T) and free PSA (PSA-Free) were measured by an ultra-sensitive fluoroimmunometric DELFIA assay (Prostatus PSA Free/Total Wallac, Turku, Finland). The detection limit for PSA was 0.01 ng/ml. Endometrial samples have been obtained with Pipelle probe between 22 and 24 days of the menstrual cycle. Results: In the control group secretory endometrium was more frequently detected than in the mastopathy group (chi2=11,15, p=0.01). Proliferatory (chi2=8.27, p=0.004) and presecretory endometrium (chi2=4.61, p=0.03) were more frequently detected in the mastopathy group than in controls. We did not find statistically significant relationship between the mean PSA concentrations between the groups in relation to histopathological findings. Conclusions: No relationships between free and total PSA measured in the follicular phase of the menstrual cycle and endometrial findings were detected in our study. Further research is required to evaluate the relationship between PSA and endometrial findings.
Get Citation

Keywords

prostate specific antigen, Mastopathy

About this article
Title

Prostate specific antigen - PSA and histopathological findings of endometrium in women with fibrocystic breast disease

Journal

Ginekologia Polska

Issue

Vol 81, No 2 (2010)

Bibliographic record

Ginekol Pol 2010;81(2).

Keywords

prostate specific antigen
Mastopathy

Authors

Stanisław Radowicki
Michał Kunicki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl